Three months in

Foundayo (orforglipron) went on sale in April 2026 as the first GLP-1 weight-loss pill you can take any time of day (Lilly, April 2026). Three months is long enough for the first wave of users to reach the middle of the dose ladder and start reporting back, and the forums are now full of the question this article answers: how's it actually going?

A ground rule first. Individual reports are anecdotes, and anecdotes skew loud: the thrilled and the miserable post, the fine-and-steady mostly don't. So we'll read the recurring themes, then check them against the trial base rate, which is what science does with stories.

Reading from the UK? Orforglipron is US-only for now: the FDA approved it in April 2026 and no MHRA decision has been announced. These early reports are your preview of what's coming; where the UK timeline stands is covered in our UK Foundayo guide.

What people consistently praise

• The no-rules tablet. The single most repeated theme. No injection day, no fridge, no 8-hour fast or 30-minute wait like the Wegovy pill demands. It travels, it fits shift work, it disappears into a normal morning. People who quit injections over needle dread describe it as the difference between managing a treatment and just taking a tablet.
• Appetite quieting that feels familiar. Switchers from injectables mostly report the same food-noise reduction, arriving gradually as doses step up.
• Predictable supply. A tablet in a bottle ships easily; the pen shortages of past years haven't had an equivalent so far.

What people struggle with

• The early-step stomach. Nausea, reflux and general digestive protest during the first dose levels dominate the complaints, exactly as the trials predicted, and mostly easing with time and slower titration (Trends Pharmacol Sci, 2026).
• Patience with the ladder. Six dose levels means months at doses that do noticeably less than the top one. People who expected injection-scale results by month two report disappointment that is really a calendar problem.
• Payment-route confusion. Self-pay, savings card and the Part D pilot produce wildly different monthly numbers, and plenty of people discover a cheaper route only after months on a dearer one (Lilly coverage page).

Anecdotes vs the base rate

The trial number to hold onto: in ATTAIN-1, people at the highest dose averaged about 12% body-weight loss over 72 weeks, with more than a third losing 15% or more (Lilly, ATTAIN-1). That is genuinely strong for a tablet, and clearly below tirzepatide's ~21%. So when one poster reports 8% in four months and another reports almost nothing yet, both can be telling the truth; the spread is the base rate doing what base rates do, and most users in July 2026 are still climbing the ladder anyway.

A note for Zepbound switchers

The most useful framing we've seen from switchers: you are trading average power for daily convenience, on purpose. If injections were working and the routine was fine, the maths rarely favours switching. If the routine was the thing failing, the needle skipped, the pen not reordered, then a tablet you actually take beats an injection you don't, by any measure that matters.

Making your own experience legible

Three months of "how's it going?" deserves better than memory. Log the daily tablet, each dose step, your weight and any side effects, and your own base rate emerges within weeks: what each rung of the ladder does to your appetite, your symptoms and your trend line. Our Foundayo calculator maps the ladder to dates, and the full Foundayo guide covers the drug itself. Track yours free.